An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

J. Davies, A. Ingham*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume487
Issue number1-2
Early online date30 Mar 2015
DOIs
Publication statusPublished - 20 Jun 2015

Bibliographical note

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).

Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.

Keywords

  • BPR
  • cholecalciferol
  • efficacy
  • regulation No. 528/2012
  • transdermal
  • rodenticide

Fingerprint Dive into the research topics of 'An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management'. Together they form a unique fingerprint.

  • Cite this